Neuronetics Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics or view top-rated stocks.

Wall Street analysts have given Neuronetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neuronetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Neuronetics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 473,400 shares, a drop of 23.7% from the February 28th total of 620,800 shares. Based on an average trading volume of 494,300 shares, the days-to-cover ratio is presently 1.0 days.
View Neuronetics' Short Interest.

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Neuronetics.

Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Monday, March, 1st. The company reported ($0.19) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.05. The business had revenue of $15.58 million for the quarter, compared to the consensus estimate of $15.21 million. Neuronetics had a negative net margin of 61.44% and a negative trailing twelve-month return on equity of 88.76%.
View Neuronetics' earnings history.

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STIM stock has increased by 517.9% and is now trading at $12.79.
View which stocks have been most impacted by COVID-19.

Neuronetics issued an update on its FY 2021 Pre-Market earnings guidance on Tuesday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $58-62 million, compared to the consensus revenue estimate of $62.58 million.

5 brokerages have issued 1 year price targets for Neuronetics' shares. Their forecasts range from $8.00 to $25.00. On average, they expect Neuronetics' share price to reach $19.25 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts' price targets for Neuronetics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Neuronetics include Atrion (ATRI), SI-BONE (SIBN), Tactile Systems Technology (TCMD), LeMaitre Vascular (LMAT), Cerus (CERS), OrthoPediatrics (KIDS), AngioDynamics (ANGO), CryoLife (CRY), Orthofix Medical (OFIX), Surmodics (SRDX), OraSure Technologies (OSUR), Antares Pharma (ATRS), Intersect ENT (XENT), Invo Bioscience (IVOB) and SeaSpine (SPNE).
View all of STIM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STIM stock can currently be purchased for approximately $12.79.

Neuronetics has a market capitalization of $324.97 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

Neuronetics employs 126 workers across the globe.

The official website for Neuronetics is www.neurostar.com.

Neuronetics is headquartered at 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at (610) 640-4202 or via email at [email protected]